Top Markets
#1 Islamic Coin Islamic Coin +152.30%
#2 Bitway Bitway +48.48%
#3 Starpower Starpower +39.10%
#4 aelf aelf +28.38%
#5 Wrapped STX (Velar) Wrapped STX (Velar) +28.38%
#6 SkyAI SkyAI +21.40%
#7 Pons Pons +16.95%
#8 DAPPOS DAPPOS +14.12%
#9 FGRS (Figure Tokenized Stock) FGRS (Figure Tokenized Stock) +14.08%
#10 Decred Decred +14.08%
Coin of the day
Islamic Coin Islamic Coin
Tetapan
Bahasa
MALAY
Mata wang
USD
Tema
Medivir AB (publ) Medivir AB (publ)

Medivir AB (publ)

MVIR-B
Kedudukan dalam Saham #29651
Medivir AB (publ) is a pharmaceutical company established in 1987 and... Medivir AB (publ) is a pharmaceutical company established in 1987 and headquartered in Huddinge, Sweden. It is dedicated to the research, development, and global commercialization of medicines, with a primary focus on oncology. The company currently markets Zoviduo (formerly Xerclear) for the treatment of labial herpes. Its robust development pipeline includes Remetinostat, targeting MF cutaneous T-cell lymphoma and basal cell carcinoma; MIV-818, aimed at liver cancer; and MIV-711, being advanced for osteoarthritis. Additionally, Medivir is progressing Birinapant and IGM-8444 for various solid tumor indications. Collaborative efforts are also key to its strategy, including a research partnership with SciLifeLab's Drug Discovery and Development Platform to discover antivirals for SARS CoV-2, alongside licensing agreements with Tango Therapeutics for a preclinical research program and with Ubiquigent Limited for the USP7 preclinical research program.
Harga Saham
$0.68377137
Disegerakkan terakhir: 2023-05-23
Modal Pasaran
$20.23M
Perubahan (1 hari)
-0.60%
Perubahan (1 tahun)
0.00%
Negara
SE
Perdagangan Medivir AB (publ) (MVIR-B)

Kategori

Healthcare
Pendapatan untuk Medivir AB (publ) (MVIR-B)
Pendapatan pada 2026 TTM: 0
Menurut laporan kewangan terkini Medivir AB (publ), pendapatan semasa syarikat ialah 0. Pada tahun 2026, syarikat memperoleh pendapatan sebanyak 0, sama dengan pendapatan pada tahun 2026 yang berjumlah 0. Pendapatan yang dipaparkan di halaman ini adalah pendapatan sebelum faedah dan cukai atau dikenali sebagai EBIT.
Sejarah pendapatan bagi Medivir AB (publ) dari 2026 hingga 2026
Pendapatan pada akhir setiap tahun
Tahun Pendapatan Ubah
Tidak cukup data untuk tarikh yang disediakan.
Pendapatan untuk syarikat atau pesaing serupa
Syarikat Pendapatan Perbezaan Pendapatan Negara
Vertex Pharmaceuticals Incorporated Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
VRTX.US
$5.27B -
US
Argenx SE Argenx SE
Argenx SE
ARGX.US
$1.95B -
NL
CSL Limited CSL Limited
CSL Limited
CSL.AX
$1.61B -
AU
Lonza Group AG Lonza Group AG
Lonza Group AG
LONN.SW
- -
CH
Samsung Biologics Co.,Ltd. Samsung Biologics Co.,Ltd.
Samsung Biologics Co.,Ltd.
207940.KS
- -
KR